IQVIA study reveals Medicare Part D plans frequently deny initial access to medications for chronic conditions, highlighting payer policy and compliance challenges.

The U.S. administration advances a 'most favored nation' drug pricing policy to align Medicare prices with global low points, aiming to reduce prescription costs amid industry resistance and anticipated legal challenges.